drugset / Trial / NCT03413020

Tailored Therapy for Helicobacter Pylori Rescue Treatment

NCT03413020

Phase 4 Completed 200 enrolled Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

With increasing antibiotic resistance and unsatisfactory results of empiric eradication regimens, tailored therapy may be the best choice to achieve high efficacy for rescue treatment. This study aimed to evaluate the eradication rates, safety, and compliance of antimicrobial susceptibility-based tailored therapy for rescue treatment in patients with Helicobacter pylori infection.

Timeline

Start
2018-01-03
Primary completion
2018-07-31
Completion
2018-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g
Subject Bismuth Potassium Citrate Unknown 220 mg
Subject Clarithromycin Small molecule 500 mg
Subject Esomeprazole Small molecule 20 mg
Subject Levofloxacin Small molecule 500 mg
Subject Metronidazole Small molecule 400 mg